Financial Data and Key Metrics Changes - Net revenue for the first quarter was $94 million, down 7% year-over-year and down 9% on a constant currency basis [12] - Product revenue was $37 million, a decrease of 23% year-over-year and down 24% on a constant currency basis [12] - Service revenue was $57 million, up 7% year-over-year and up 4% on a constant currency basis [13] - Overall gross margin for the quarter was 28.3%, compared to 33.9% in the prior year [14] - Adjusted EBITDA for the quarter was a loss of $4.1 million, compared to an income of $3.1 million in the prior year [17] Business Line Data and Key Metrics Changes - Product revenue decline was attributed to slower performance in EMEA and China regions [12] - Service revenue growth was driven by a 10% increase in contract revenue year-over-year [13] - Product orders for the first quarter were approximately $40 million, with a book-to-bill ratio of 1.1 [13] Market Data and Key Metrics Changes - The company experienced a slowdown in EMEA and China, while the U.S. market showed stability [25] - The company reported gross orders of about $40 million, lower than expectations due to timing of customer receipts in the Americas and China [26] Company Strategy and Development Direction - The immediate goal is to identify key strategic, operational, and financial areas necessary for competitive positioning and margin expansion [6][8] - The transformation plan aims to enhance organizational responsiveness and agility, targeting a high single-digit adjusted EBITDA margin within 12 months [9] - The company plans to provide more details on the transformation plan in early 2026 [19] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential for enhancing performance and long-term growth prospects [5] - The company reiterated its fiscal year 2026 guidance with revenue expected in the range of $471 million to $485 million [18] - Management noted that geopolitical and macroeconomic uncertainties are ongoing but expressed confidence in achieving adjusted EBITDA guidance [20] Other Important Information - The company initiated a restructuring plan resulting in $2.8 million in restructuring charges [17] - The company ended the first quarter with a reporting order backlog of approximately $396 million, providing strong visibility for future revenue conversion [13] Q&A Session Summary Question: What is the current capital equipment purchasing environment? - The response indicated a varied environment by region, with a slowdown in EMEA and China but stability in the U.S. and growth in APAC [25] Question: What contributed to the difference between gross and net orders? - The response noted that age outs occurred but were not out of the norm, with lower gross orders primarily due to timing of customer receipts [26] Question: Any updates on tariff mitigation efforts? - The company is actively pursuing a duty drawback program and considering the implementation of a foreign trade zone to mitigate tariffs [27] Question: What is the expected revenue split between the first and second half of the fiscal year? - Management expects first half revenue to be about 40% of full-year guidance and second half to be about 60% [29] Question: How will product gross margins be affected in the upcoming quarters? - The response indicated that product gross margins are expected to improve in the second half as more deals in developed markets are executed [32]

Performance Overview - The Third Avenue Small-Cap Value Fund returned 7.18% in Q3 2025, underperforming the MSCI USA Small Cap Value Index at 8.97% and the Russell 2000 Value Index at 12.60% [2] - The Fund's annualized returns for the trailing three-year and five-year periods were 15.11% and 16.09%, respectively [2] Positive Contributors - Supernus Pharmaceuticals (SUPN) was the largest positive contributor, benefiting from a strong financial position, profitability, an expanding neurology drug portfolio, and a successful acquisition [3] - Investors Title Company (ITIC) saw positive performance due to increased real estate refinancing activity [3] - UMB Financial Corporation (UMBF) successfully integrated its acquisition of Heartland Financial, showcasing operational competence [3] Negative Contributors - Atlanta Braves Holdings (BATRA) was a negative contributor, though it is perceived to have an attractive asset base and potential for favorable resource conversion [4] - UniFirst Corporation (UNF) faced pressure to demonstrate its value proposition after rejecting an acquisition offer from Cintas Corporation (CTAS) [4] - FRP Holdings (FRPH) was impacted by a lack of confidence in government spending affecting the D.C. metro area [4] Investment Strategy - The Fund focuses on acquiring companies in transitional states, aiming to capitalize on undervalued businesses with potential for future growth [5] - Investment activity emphasizes companies that are well-financed, trading at discounts to net asset value, and have identifiable levers for value creation [6] - The Fund's turnover rate is approximately 20%, indicating a long-term investment horizon of about five years, contrasting with the average turnover of 91.7% in the small-cap value fund universe [7] Types of Investment Opportunities - The Fund identifies three broad types of investment opportunities: 1. Companies facing industry-wide headwinds that can improve through restructuring [9] 2. Companies with current economic returns that have underappreciated self-help opportunities [9] 3. Event-driven situations that offer unique return profiles through transformational changes [9] Recent Transactions - Ambac Financial (AMBC) completed the sale of its legacy financial guarantee business, leading to a significant cash inflow and a transformation towards insurance distribution [11][12] - The Fund initiated new positions in Boise Cascade (BCC) and Rogers Corporation (ROG) during the quarter, while also adding to existing positions like UniFirst Corporation (UNF) [14] Company Profiles - Boise Cascade is a leading manufacturer and distributor of building materials, facing challenges due to slowing housing activity but retaining a strong financial position [15][16] - Rogers Corporation specializes in electronic and materials technology solutions, facing growth challenges but possessing valuable intellectual property and a strong balance sheet [18][19][20]

Core Insights - Accuray Incorporated is undergoing a significant organizational, strategic, and operational transformation to enhance competitiveness and drive sustainable growth [1][3] - Steve La Neve has been appointed as the new CEO, succeeding Suzanne Winter, who will retire after six years [2][3] - The transformation plan aims to increase operating margins and improve organizational agility, with most initiatives set to be implemented in the current fiscal year [1][3] Leadership Changes - Steve La Neve brings over 40 years of medical-technology experience and a proven track record in operational excellence and revenue growth [3][4] - Steven F. Mayer has been appointed as Transformation Board Sponsor to oversee the execution of the transformation initiatives [5][6] - Chan W. Galbato has been nominated to the Board of Directors, bringing over 30 years of operational and strategic leadership experience [7] Financial Performance - Accuray expects total revenues for the fiscal 2026 first quarter to be between $92.5 million and $94 million, with service revenues exceeding plans but product revenues falling short in EIMEA and China [8][9] - The company anticipates reaching a high single-digit adjusted EBITDA margin run-rate within twelve months, aiming for double-digit margins in the medium to long term [6][8]

Core Insights - Johnson & Johnson's stock has increased over 23% year-to-date, indicating strong investor confidence despite ongoing legal challenges [1] - The strategic separation of its consumer health division has transformed Johnson & Johnson into a more agile company focused on high-margin, high-growth sectors [2][3] - The company is now dedicated to innovative medicine and medical technology, moving away from legacy lawsuit risks towards a clearer growth path [3] Financial Performance - The 2023 spinoff of the consumer health business, now Kenvue, has allowed Johnson & Johnson to focus on pharmaceuticals and MedTech, enhancing shareholder value [4] - In Q2 2025, total revenues reached $23.74 billion, with Innovative Medicine contributing $15.20 billion and MedTech $8.54 billion [5] - Management raised its full-year sales guidance by $2 billion, reflecting a sharpened focus on high-return opportunities [6] Pharmaceutical Division Strength - Johnson & Johnson's pharmaceutical division is robust, with a strong portfolio of drugs offsetting anticipated challenges [7] - The oncology franchise saw a remarkable 22.3% operational sales growth in Q2, driven by successful products like Darzalex and Carvykti [12] - The company is managing the transition of Stelara effectively, with its successor Tremfya growing 30.1% [12] MedTech Division Growth - The MedTech division achieved 6.1% operational growth in Q2, with the cardiovascular business expanding by 22% [9] - Recent acquisitions, such as Abiomed and Shockwave Medical, are exceeding expectations and establishing Johnson & Johnson as a leader in high-growth cardiovascular markets [10] Future Growth Potential - Johnson & Johnson's late-stage pipeline indicates a clear path to future revenue, with the FDA granting Priority Review for TAR-200 and a recent application for icotrokinra [12] - The company's M&A strategy adds diversification and financial strength, supporting long-term liabilities while maintaining innovation [11] Investment Appeal - Johnson & Johnson is trading at a forward P/E ratio of 16.88, offering a blend of growth potential and financial stability [13] - The company has a strong dividend history, with a yield of 2.91% and a sustainable payout ratio of 55.6% of earnings, indicating safety and room for growth [18]

Core Insights - Allied Critical Metals Inc. has appointed Major General (Ret.) James A. "Spider" Marks to the Board of Directors of its U.S. subsidiary, Allied Critical Metals (USA), Inc. This move aims to strengthen the company's operations in the U.S. tungsten market [1][3]. Company Overview - Allied Critical Metals Inc. is a Canadian-based mining company focused on the Borralha and Vila Verde tungsten projects in northern Portugal, which are 100% owned by the company [1][6]. - The company is dedicated to the importation, marketing, and sales of tungsten in the United States, addressing the growing demand for this critical mineral [1][5]. Leadership and Expertise - General Marks brings over four decades of leadership experience from military, intelligence, and commercial sectors, including significant roles in the U.S. Army and executive positions in private industry [2][3]. - His expertise in global defense, logistics, and strategy is expected to enhance Allied USA's operational and strategic direction, particularly in securing reliable tungsten supply chains for the U.S. [3][4]. Market Context - Tungsten is classified as a critical mineral essential for industries such as aerospace, defense, and electronics. The tungsten market is valued at approximately USD $5 to $6 billion [6]. - The U.S. is actively seeking to diversify its sources of tungsten, as current global supply is heavily dominated by China, Russia, and North Korea, which account for about 86% of total global supply and reserves [6].

Core Insights - Fresenius Medical Care (FME) successfully executed its strategic plan during the 2024 fiscal year, laying a strong foundation for sustainable and profitable growth [1][2] - The company completed its first full fiscal year as a stock corporation, achieving significant milestones in debt reduction and operational realignment [2] - The company reported a 4% organic revenue growth and an 18% increase in operating income, positioning itself for double-digit earnings growth in 2025 [3] Financial Performance - The Care Delivery segment achieved a margin contribution of over 10%, reaching the lower end of its target band of 10-14% [2] - Care Enablement demonstrated a strong margin performance of 6.1% in 2024, nearly tripling its prior year contribution and entering its target margin band of 8-12% in Q1 2025 [2] - The company set a new savings target of 750 million Euro for its FME25 transformation program, a 50% increase from the original target of 500 million Euro [2] Shareholder Returns - A dividend of 1.44 Euro per share was approved, representing a 21% increase from the previous year and marking the highest dividend in the company's history [2][3] - 96.85% of shareholders approved the proposed dividend at the Annual General Meeting [2] Corporate Governance - The compensation report for the Management Board and Supervisory Board was approved with a majority of 88.57% [3] - Authorizations for the Management Board to increase share capital and issue option or convertible bonds were renewed, allowing for flexible financing options [5][4] Market Position - Fresenius Medical Care is the leading provider of products and services for individuals with renal diseases, serving approximately 4.2 million patients globally [7] - The company operates 3,674 dialysis clinics and is recognized for its innovative dialysis products, including the FDA-approved 5008X machine for high-volume hemodiafiltration dialysis therapy [2][7]

Core Viewpoint - B. Riley Financial has appointed Scott Yessner as the new Chief Financial Officer, effective June 3, 2025, succeeding Phillip Ahn, who is leaving for another opportunity [1][3]. Group 1: Appointment Details - Scott Yessner has been a strategic advisor for B. Riley Financial for the past two months prior to his appointment [1]. - Phillip Ahn has been with B. Riley for over a decade and has played a significant role in the company's executive team [3]. Group 2: Scott Yessner's Background - Mr. Yessner has extensive experience as a CFO, having previously improved EBITDA by $40 million at CEMCO and $45 million at Universal Technical Institute, with the latter seeing a 250% increase in stock price during his tenure [2][4]. - He has also held executive roles at Wells Fargo Advisors and MUFG Union Bank, and has experience advising private equity firms [5]. Group 3: Company Insights - B. Riley Financial is a diversified financial services company that provides a wide range of solutions including investment banking, private wealth management, and corporate restructuring [6]. - The company aims to deliver tailored solutions to meet the strategic, operational, and capital needs of its clients [6].